Dynamic assays of inhibin B and oestradiol following buserelin acetate administration as predictors of ovarian response in IVF

Hum Reprod. 2000 Nov;15(11):2297-301. doi: 10.1093/humrep/15.11.2297.

Abstract

The study was designed to examine whether dynamic measurements of inhibin B and oestradiol following single administration of buserelin acetate were correlated with the ovarian response to stimulation in IVF. A total of 37 patients undergoing IVF treatment was studied when the long protocol was started in the early follicular phase. Blood samples were taken twice: on day 2 of the menstrual cycle, before the first s.c. administration of buserelin acetate 0.5 mg and on day 3, 24 h later. Inhibin B and oestradiol concentrations were compared with the ovarian response to stimulation. The ovarian response was defined in two ways: 'number of oocytes/total recombinant (r) follicle stimulating hormone (FSH) dose'; and 'square-root (number of follicles/total rFSH dose)'. The following measurements were highly correlated with the ovarian response to stimulation: increase in oestradiol (day 3-day 2 oestradiol concentration) [correlation coefficient (r) = 0.68, P: < 0.0001] and sum of inhibin B (day 2 + day 3 inhibin B concentrations) (r = 0.6, P: < 0.0001). Age and basal concentrations of FSH and inhibin B were inferior to the above measurements in terms of correlation with the ovarian response. In conclusion, dynamic measurements of inhibin B and oestradiol following single administration of buserelin acetate were highly correlated with the ovarian response to stimulation for IVF treatment.

MeSH terms

  • Adult
  • Buserelin / therapeutic use*
  • Cell Count
  • Dose-Response Relationship, Drug
  • Estradiol / blood*
  • Female
  • Fertility Agents, Female / therapeutic use*
  • Fertilization in Vitro*
  • Follicle Stimulating Hormone / administration & dosage
  • Follicle Stimulating Hormone / therapeutic use
  • Forecasting
  • Humans
  • Infertility, Female / pathology
  • Infertility, Female / therapy
  • Oocytes / pathology
  • Ovarian Follicle / pathology
  • Ovary / drug effects*
  • Ovary / physiopathology*
  • Peptides / blood*
  • Prostatic Secretory Proteins*
  • Recombinant Proteins / administration & dosage
  • Recombinant Proteins / therapeutic use
  • Treatment Outcome

Substances

  • Fertility Agents, Female
  • Peptides
  • Prostatic Secretory Proteins
  • Recombinant Proteins
  • beta-microseminoprotein
  • Estradiol
  • Follicle Stimulating Hormone
  • Buserelin